参考文献 - Ahannan SV, Brahmer JR. Antiangiogenic agents in combination with chemotherapy in patients with advanced non-small cell lung cancer. Cancer Invest, 2011, 29(4): 325-337.[LinkOut]
- Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med, 2002, 346(2): 92-98.[LinkOut]
- Smit EF, van Meerbeeck JP, Lianes P, et al. Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group-EORTC 08975. J Clin Oncol, 2003, 21(21): 3909-3917.[LinkOut]
- Balak MN, Gong Y, Riely GJ, et al. Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res, 2007, 13(11): 3431-3432.[LinkOut]
- Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science, 2004, 304(5676): 1497-1500.[LinkOut]
- Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med, 2004, 350(21): 2129-2139.[LinkOut]
- Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA, 2004, 101(36): 13306-13311.[LinkOut]
- Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med, 2009, 361(10): 947-957.[LinkOut]
- Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol, 2009, 11(2): 121-128.[LinkOut]
- Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med, 2010, 362(25): 2380-2388.[LinkOut]
- Janne PA. Challenges of detecting EGFR T790M in gefitinib/erlotinibresistant tumours. Lung Cancer, 2008, 60(Supp2): s3-s9.[LinkOut]
- Uramoto H, Sugio K, Oyama T, et al. A resistance to gefitinib. Int J Clin Oncol, 2006, 11(6): 487-491.[LinkOut]
- Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med, 2005, 353(2): 786-792.[LinkOut]
- Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science, 2007, 316(5827): 1039-1043.[LinkOut]
- Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med, 2005, 2(3): e73.[LinkOut]
- Yamamoto C, Basaki Y, Kawahara A, et al. Loss of PTEN expression by blocking nuclear translocation of EGR1 in gefitinib-resistant lung cancer cells harboring EGFR activating mutations. Cancer Res, 2010, 70(21): 8715-8725.[LinkOut]
- Onitsuka T, Uramoto H, Nose N, et al. Acquired resistance to gefitinib: the contribution of mechanisms other than the T790M, MET, and HGF status. Lung Cancer, 2010, 68(2): 198-203.[LinkOut]
- Uramoto H, Iwata T, Onitsuka T, et al. Epithelial-mesenchymal transition in EGFR-TKI acquired resistant lung adenocarcinoma. Anticancer Res, 2010, 30(7): 2513-2517.[LinkOut]
- Giaccone G, Wang Y. Strategies for overcoming resistance to EGFR family tyrosine kinase inhibitors. Cancer Treat Rev, 2011, 37(6): 456-464.[LinkOut]
- Jia G, Zhang WM, Wang L, et al. Sequence-dependent effect of docetaxel with gefitinib on the proliferation and signal protein expression of human lung adenocarcinoma cell SPC-A1. Zhongguo Fei Ai Za Zhi, 2010, 14(5): 385-390. [贾刚, 张为民, 王林, 等. 多西他赛与吉非替尼序贯应用对人肺腺癌细胞SPC-A1生长及信号蛋白的影响. 中国肺癌杂志, 2010, 14(5): 385-390.][LinkOut]
- Cheng H, An SJ, Dong S, et al. Molecular mechanism of the schedule-dependent synergistic interaction in EGFR-mutant non-small cell lung cancer cell lines treated with paclitaxel and gefitinib. J Hematol, 2011, 4(5): 1-13.[LinkOut]
- Wu JY, Shih JY, Yang CH, et al. Second line treatmens after first line gefitinib therapy in advanced non-small cell lung cancer. Int J Cancer, 2010, 126(1): 247-255.[LinkOut]
- Yano S, Nakataki E, Ohtsuka S, et al. Retreatment of lung adenocarcinom a patients with gefitinib who had experienced favorable results from their initial treatment with this selective epidermal growth factor receptor inhibitor: a report of three cases. Oncol Res, 2005, 15(2): 107-111.[LinkOut]
- Riely GJ, Janjigian YY, Azzoli CG, et al. Phase III trial of cetuximab and erlotinib in patients with lung adenocarcinoma and acquired resistance to erlotinib. J Clin Oncol, 2010, 28(7Suppl): a7557.[LinkOut]
- Steel GG, Peckham MJ. Exploitable mechanisms in combined radiotherapychemotherapy: the concept of additivity. Int J Radiat Oncol Biol Phys, 1979, 5(1): 85-91.[LinkOut]
- Kano Y, Ohnuma T, Okano T, et al. Effects of vincristine in combination with methotrexate and other anti-tumor agents in human acute lymphoblastic leukemia cells in culture. Cancer Res, 1988, 48(2): 351-356.[LinkOut]
- Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res, 2010, 70(2): 440-446.[LinkOut]
- Yun CH, Mengwasser KE, Toms AV, et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci USA, 2008, 105(6): 2070-2075.[LinkOut]
- Sos ML, Rode HB, Heynck S, et al. Chemogenomic profiling provides insights into the limited activity of irreversible EGFR inhibitors in tumor cells expressing the T790M EGFR resistance mutation. Cancer Res, 2010, 70(3): 868-874.[LinkOut]
- Cheng H, An SJ, Zhang XC, et al. In vitro sequence-dependent synergism between paclitaxel and gefitinib in human lung cancer cell lines. Cancer Chemother Pharmacol, 2011, 67(3): 637-646.[LinkOut]
- Gridelli C, Maione P, Galetta D, et al. Three cases of long-lasting tumor control with erlotinib after progression with gefitinib in advanced non-small cell lung cancer. J Thorac Oncol, 2007, 2(8): 758-761.[LinkOut]
- Buck E, Eyzaguirre A, Brown E, et al. Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors. Mol Cancer Ther, 2006, 5(11): 2676-2684.[LinkOut]
- Herbst RS, Prager D, Hermann R, et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol, 2005, 23(25): 5892-5899.[LinkOut]
- Gatzemeier U, Pluzanska A, Szczesna A, et al. Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC). J Clin Oncol, 2004, 23(14S): 617.
- Chang GC, Hsu SL, Tsai JR, et al. Molecular mechanisms of ZD1839- induced G1-cell cycle arrest andapoptosis in human lung adenocarcinoma A549 cells. Biochem Pharmacol, 2004, 68(7): 1453-1464.[LinkOut]
- Klass CM, Choe MS, Hurwitz SJ, et al. Sequence dependence of cell growth inhibition by EGFR-tyrosine kinase inhibitor ZD1839, docetaxel, and cisplatin in head and neck cancer. Head Neck, 2009, 31(10): 1263-1273.[LinkOut]
- Giovannetti E, Lemos C, Tekle C, et al. Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells. Mol Pharmacol, 2008, 73(4): 1290-1300.[LinkOut]
|